Pharmacologic targeting of the dopamine D2 receptor impacts the efficacy of immune checkpoint blockade in melanoma
These findings demonstrate that pharmacologic modulation of D2R impacts the efficacy of immune checkpoint blockade in murine melanoma and raise the possibility of using FDA-approved D2R targeting therapies as cotherapeutics to overcome ICI resistance in patients with advanced melanoma.
Authors
- Heather M. Gibson (ORCID: https://orcid.org/0000-0003-2652-8252)
- Maria C. Muñiz (ORCID: https://orcid.org/0000-0002-8392-3905)
- Mark Gregory (ORCID: https://orcid.org/0000-0003-4149-4724)
- Justin Hackett (ORCID: https://orcid.org/0000-0002-3377-1499)
- Greg Dyson
- Steven Daveluy (ORCID: https://orcid.org/0000-0002-6951-2894)
- Hanna A. Holland (ORCID: https://orcid.org/0000-0002-7164-1572)
- S. Hughes
- Habib Alrabaa
- Alexander Boerner
- Brianna Rivera
- Lucien Taylor
- Samantha Ayoub
Institutions
- Wayne State University (US)
- University of Washington (US)
- Michigan State University (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1136/jitc-2025-014080
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00